Skip to content

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status
Selina Luger, MD, weighs the promise and challenges of modern ALL care
Advancing care through collaborative science: A European perspective
SOHO 2026 Friday plenary features NIH scientist and aplastic anemia expert Dr. Neal S. Young
Dr. Maddocks previews Friday MCL session at SOHO 2026

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

MPN News

Myeloproliferative Neoplasms Polycythemia Vera News

FDA approves first-in-class therapy for polycythemia vera

by SOHO Insider Editors
August 31, 2026
0 Comments

ASCO 2026 Myelodysplastic Syndromes Myeloproliferative Neoplasms Video Interviews

Fedratinib demonstrates favorable OS in MDS/MPN overlap syndrome

by SOHO Insider Editors
August 11, 2026
0 Comments

Leukemia Chronic Lymphocytic Leukemia Lymphoma Aggressive B-Cell Lymphomas Myeloproliferative Neoplasms News

FDA approves rituximab biosimilar for B-cell malignancies

by SOHO Insider Editors
August 3, 2026
0 Comments

ASCO 2026 Meetings / Conferences Myeloproliferative Neoplasms News

Selinexor plus ruxolitinib meaningfully improves spleen response in MF trial

by SOHO Insider Editors
July 22, 2026
0 Comments

ASCO 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis Video Interviews

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

by SOHO Insider Editors
July 14, 2026
0 Comments

EHA 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis

Dr. Naseema Gangat discusses initial data from RALLY-MF trial

by SOHO Insider Editors
July 10, 2026
0 Comments

Myeloproliferative Neoplasms Polycythemia Vera News

FDA approves ropeginterferon alfa-2b-njft pen for polycythemia vera

by SOHO Insider Editors
July 8, 2026
0 Comments

EHA 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis Video Interviews

Early-phase trial data of INCA033989 shows durable responses in MF

by Leah Sherwood
June 26, 2026
0 Comments

Myeloproliferative Neoplasms Polycythemia Vera

Taiwan regulatory body approves ropeginterferon alfa-2b-njft in ET

by SOHO Insider Editors
June 24, 2026
0 Comments

EHA 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis

Post-transplant molecular monitoring could prompt preemptive intervention in patients with myelofibrosis

by Kerri Fitzgerald
June 19, 2026
0 Comments

1
2
3
4

Top Categories

Cellular Therapy

82

Leukemia

133

Lymphoma

141

Multiple Myeloma

120

Myelodysplastic Syndromes

49

Myeloproliferative Neoplasms

36

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

MPN News

FDA approves first-in-class therapy for polycythemia vera

Fedratinib demonstrates favorable OS in MDS/MPN overlap syndrome

FDA approves rituximab biosimilar for B-cell malignancies

Selinexor plus ruxolitinib meaningfully improves spleen response in MF trial

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial

Dr. Naseema Gangat discusses initial data from RALLY-MF trial

FDA approves ropeginterferon alfa-2b-njft pen for polycythemia vera

Early-phase trial data of INCA033989 shows durable responses in MF

Taiwan regulatory body approves ropeginterferon alfa-2b-njft in ET

Post-transplant molecular monitoring could prompt preemptive intervention in patients with myelofibrosis

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status

Selina Luger, MD, weighs the promise and challenges of modern ALL care

Advancing care through collaborative science: A European perspective

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

MPN News

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms